Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients：An Exploratory Single-Arm Phase II Clinical Trail

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03672136
• Other study ID #: ALTER0300
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: November 1, 2018
• Est. completion date: November 1, 2020

Study information

• Verified date: September 2018
• Source: Shandong Cancer Hospital and Institute
• Contact: Ming Huan Li, doctor
• Phone: 131 5303 5389
• Email: sy_lmh2001[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether concurrent chemoradiotherapy combination with Anlotinib is safe, effective in the treatment of unresectable stage III NSCLC patients.

Description:

The purpose of this study is to determine whether concurrent chemoradiotherapy combination with Anlotinib is safe, effective in the treatment of unresectable stage III NSCLC patients, whether this regimen can improve PFS.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 25
• Est. completion date: November 1, 2020
• Est. primary completion date: November 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients voluntarily participate in this study, signed informed consent.

2. Patients pathologically diagnosed as locally advanced (IIIB / IV) unresectable non-small cell lung cancer, with measurable lesions; IIIa3 patient: Multiple stations lymph node metastasis detected by mediastinoscope, other lymph node biopsy or PET-CT; IIIa4 patient: Bulky or stable multiple stations N2 lymph node metastasis (Bulky lymph node: short diameter > 2cm in spiral CT imaging, especially the extranodal invasion); and IIIb patient; T3/4 patient with several ipsilateral or contralateral satellite nodules metastasis will be excluded.

3. Detection of genotypes by providing detectable specimens (tissue) prior to enrollment:

patients with negative EGFR mutation, or ALK rearrangement test results.

4. Patients aged between 18 -75 years; with ECOG PS Scoring: 0~1 point; with expected survival time>3 months.

5. Patients with normal organ function within 7 days prior to treatment, the following criteria are met:

a) blood routine examination criteria (without blood transfusion in 14 days) : i) hemoglobin (HB) =100g/L; ii) white blood cell (WBC)= 3.0×10e9/L, absolute neutrophil count (ANC) =1.5×10e9/L; iii) platelet (PLT) =100×10e9/L; b) biochemical tests meet the following criteria: i) total bilirubin (TBIL) =1.5 times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 ULN, if liver metastasis occurred, ALT and AST =5 ULN; iii) serum creatinine (Cr) =1.5 ULN or creatinine clearance (CCr) =60mL/min;

6. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) =50% lower limit of normal (LLN);

7. Lung function evaluation: forced expiratory volume in first second (FEVI)=1.45L/s.

Exclusion Criteria(Patient meet any criteria as following will be excluded):

1. Patients who had previously used anlotinib hydrochloride capsules;

2. Patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);

3. Patients with empty lung squamous cell carcinoma, or non-small cell lung cancer with hemoptysis (>20 mL/day);

4. Patients had other malignancies in the past 5 years or currently, except undergone resection and at least 5 years of progression free survival or cured cervical cancer in situ, basal cell carcinoma and superficial bladder tumor;

5. Patients who planned to receive systemic anti-tumor therapy within 4 weeks prior to allocation or during the course of this study, including cytotoxic therapy, signal transduction inhibitors, immunotherapy, except the immunoregulation agents, such as thymosin and lentinan;

6. Patients with more than common terminology criteria for adverse events (CTC AE) level 1 unmitigated toxicity due to any previous treatment, not including hair loss;

7. Patients have a variety of factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.);

8. Patients with pleural effusion or ascites, causing respiratory syndrome (= CTC AE level 2 dyspnea);

9. Patients with any severe and/or uncontrolled disease, including:

1. blood pressure control is not ideal (systolic blood pressure = 150 mmHg, diastolic blood pressure = 100 mmHg);

2. myocardial ischemic or myocardial infarction, arrhythmia (including QTc =480 ms) and = 2 levels of congestive heart failure (NYHA classification);

3. active or uncontrollable serious infection (=CTC AE Level 2 infection);

4. liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis need to be treated with antiretroviral therapy;

5. renal failure requires hemodialysis or peritoneal dialysis;

6. history of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease, or history of organ transplantation;

7. poor control of diabetes (fasting blood glucose [FBG]> 10 mmol/L);

8. urine routine test protein=++, and confirmed 24 hours urine protein>1.0 g;

9. patients with a seizure and need treatment;

10. Patients with gastric ulcer;

10. Received a major surgical treatment within 28 days prior to allocation, with a biopsy or a significant traumatic injury;

11. Imaging shows that the tumor has been violated around important vascular or the researchers determine the tumor is likely to invade important blood vessels caused by fatal bleeding during the follow-up;

12. Regardless of the severity, patients with any signs or medical history of bleeding; within 4 weeks prior to allocation, patients with any bleeding events = CTC AE level 3, unhealed wounds, ulcers or fractures;

13. Patients with artery/venous thrombotic occurred within 6 months before allocation, such as cerebrovascular accident (including temporary ischemic attack),deep vein thrombosis and pulmonary embolism;

14. Patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders;

15. Patients during pregnancy or lactation period;

16. Patients participated in other anti-tumor drug clinical trials within 4 weeks;

17. According to the determination of researchers, patients were diagnosed with disease which will severely endanger the security of patients or influence the completion of this research.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

Intervention

Drug:
• Anlotinib
Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD a/ß, c-Kit and Ret.

Other:
• Concurrent Chemoradiotherapy
Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients

Locations

Country	Name	City	State
China	SHANDONG Cancer Hospital and Institute	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Shandong Cancer Hospital and Institute

Country where clinical trial is conducted

China, 

References & Publications (3)

Bao Y, Peng F, Zhou QC, Yu ZH, Li JC, Cheng ZB, Chen L, Hu X, Chen YY, Wang J, Wang Y, Ma HL, Xu ZM, Lu RB, Deng XW, Chen M. Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-sma — View Citation

Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients Wit — View Citation

Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med. 1996 Nov 1;125(9):723-9. Erratum in: Ann Intern Med — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	Progression Free Survival	2 years
Secondary	OS	Overall survival	2 years
Secondary	ORR	Objective Response Rate	2 years
Secondary	DCR	Disease Control Rate	2 years